Example ImageÃÀ¸ß÷

EN
EN
  • ÓªÒµ×Éѯ

    Öйú£º

    Email: marketing@medicilon.com.cn

    ÓªÒµ×ÉѯרÏߣº400-780-8018

    £¨½öÏÞЧÀÍ×Éѯ£¬£¬ £¬£¬£¬£¬ÆäËûÊÂÒËÇ벦´ò´¨É³×ܲ¿µç»°£©

    ´¨É³×ܲ¿µç»°: +86 (21) 5859-1500

    ÍâÑó£º

    +1(781)535-1428(U.S.)

    0044 7790 816 954 (Europe)

    Email:marketing@medicilon.com

ÔÚÏßÁôÑÔ¡Á
µã»÷Çл»
News information
ÐÂÎÅ×ÊѶ

OncotelicÓëÃÀ¸ß÷ÔÚºËËáÒ©Îï¡¢ÄÉÃ×ÖÆ¼ÁµÈÁìÓò¸æ¿¢Õ½ÂÔÏàÖú

2025-02-26
|
»á¼ûÁ¿£º

Oncotelic announce a strategic partnership with Shanghai Medicilon Inc.webp

2ÔÂ25ÈÕ£¬£¬ £¬£¬£¬£¬È«ÇòÁìÏȵÄRNAÁÆ·¨ÖÆÒ©ÆóÒµOncotelic Therapeutics£¨OTCQB: OTLC£©¼°ÆäºÏ×ʹ«Ë¾GMPÉúÎï¼¼ÊõÓÐÏÞ¹«Ë¾È«×Ê×Ó¹«Ë¾Sapu Bioscience, LLC£¨Oncotelic³ÖÓÐ45%¹É·Ý£©£¬£¬ £¬£¬£¬£¬ÓëÃÀ¸ß÷£¨¹ÉƱ´úÂ룺688202.SH£©Ðû¹«¸æ¿¢Õ½ÂÔÏàÖú¡£¡£¡£

´Ë´ÎÏàÖúÖ¼ÔÚͨ¹ýÃÀ¸ß÷һվʽÉúÎïÒ½Ò©ÁÙ´²Ç°×ÛºÏÑз¢Ð§ÀÍÆ½Ì¨£¬£¬ £¬£¬£¬£¬5Äê¼ÓËÙÍÆ½øOncotelicºÍSAPU20¼þÐÂÒ©ÁÙ´²ÊÔÑéÉêÇ루IND£©ÏîÄ¿£¬£¬ £¬£¬£¬£¬ÏÖÔÚ¶à¸öÐÂÐÍ¿¹°©Ò©ÎïINDÏîÄ¿ÕýÔÚÆð¾¢ÍƽøÖС£¡£¡£

Oncotelic Accesses Rapid IND Development Platform through Partnership with Medicilon.webp

Oncotelic£ºÈ«ÇòÁìÏȵÄRNAÁÆ·¨ÖÆÒ©ÆóÒµ

OncotelicÔÚÖ×ÁöÒ©Î↑·¢ÁìÓòÒÑÉî¸û37Ä꣬£¬ £¬£¬£¬£¬×¨×¢ÓÚRNAÁÆ·¨ÓëС·Ö×ÓÒ©ÎïµÄÑз¢Á¢Ò죬£¬ £¬£¬£¬£¬ÓÈÆäÔÚÓÐÊý¶ù¿Æ°©Ö¢ÁìÓòÈ¡µÃÁ˷ḻµÄÑо¿Ð§¹û¡£¡£¡£Í¨¹ýºÏ×ÊÆóÒµÐÎʽ£¬£¬ £¬£¬£¬£¬Oncotelic»ñµÃ¶àÏîÓÐÊý²¡ÁÆ·¨È϶¨£¬£¬ £¬£¬£¬£¬°üÀ¨Õë¶ÔDIPGµÄOT-101¡¢Õë¶ÔÐþÉ«ËØÁöµÄCA4P¼°Õë¶ÔAMLµÄOXi 4503¡£¡£¡£ÒԺ󣬣¬ £¬£¬£¬£¬OncotelicÊÕ¹ºPointR Data Inc.£¬£¬ £¬£¬£¬£¬×ªÐÍΪAIÇý¶¯µÄÉúÎïÖÆÒ©¹«Ë¾ £»£»£»£»£»£»»ñAL-101¿ª·¢È¨£¬£¬ £¬£¬£¬£¬ÍýÏëÓÃÓÚÖÎÁÆÅÁ½ðÉ­²¡¡¢²ªÆð¹¦Ð§Õϰ­µÈ£¬£¬ £¬£¬£¬£¬Ò»Ö±ÍØÕ¹ÆäÑз¢¹ÜÏßÓëÖÎÁÆÁìÓò¡£¡£¡£

ÃÀ¸ß÷£ºÈ«ÇòÐÂÒ©ÁÙ´²Ç°Ñз¢Ð§À͸³ÄÜÕß

ÃÀ¸ß÷£¬£¬ £¬£¬£¬£¬×÷ΪÖйúÉÙÓеÄһվʽÉúÎïÒ½Ò©ÁÙ´²Ç°Ñз¢Ð§ÀÍÆ½Ì¨£¬£¬ £¬£¬£¬£¬Ê¼ÖÕÕ¾ÔÚ¹ú¼Ê¼¼ÊõÇ°ÑØ£¬£¬ £¬£¬£¬£¬ÀֳɴÁ˺­¸ÇADC¡¢ºËËá¡¢PROTAC¡¢¿¹Ìå¡¢¶àëÄ¡¢ÒßÃçÒÔ¼°Ï¸°ûÓë»ùÒòÖÎÁƵȶà¸öÁìÓòµÄзÖ×ÓÒ©ÎïÑз¢Ð§ÀÍÆ½Ì¨¡£¡£¡£×èÖ¹2024Äêµ×£¬£¬ £¬£¬£¬£¬ÃÀ¸ß÷ÒÑÖúÁ¦Ô¼520¼þINDÏîÄ¿»ñÅúÁÙ´²¡¢60¼þINDÏîĿʵÏÖÖÐÃÀË«±¨»ñÅú£¬£¬ £¬£¬£¬£¬»ýÀÛÁ˸»ºñµÄÖÐÃÀÅ·¶à¹úÉ걨µÄÀÖ³ÉÂÄÀú¡£¡£¡£

¾Û½¹ºËËáÒ©Îï¡¢ÄÉÃ×ÖÆ¼ÁµÈÁìÓò

ÃÀ¸ß÷ÖúÁ¦Oncotelic5ÄêÍÆ½ø20¸öINDÏîÄ¿

´Ë´ÎÏàÖú²»µ«ÊÇOncotelicºÍSAPUÔÚÐÂÐͰ©Ö¢ÁÆ·¨ÁìÓòǰհսÂԽṹÓëÉî¶ÈÑз¢ÐÅÐĵÄÉî¿ÌÌåÏÖ£¬£¬ £¬£¬£¬£¬Ò²ÊǸ÷·½Á¢ÒìÔ¸¾°¸ß¶ÈÆõºÏ¡¢ÓÅÊÆ×ÊÔ´Éî¶ÈÕûºÏµÄ¹æ·¶¡£¡£¡£

ƾ֤սÂÔЭÒ飬£¬ £¬£¬£¬£¬ÃÀ¸ß÷½«ÒÀÍÐһվʽÉúÎïÒ½Ò©ÁÙ´²Ç°×ÛºÏÑз¢Ð§ÀÍÆ½Ì¨£¬£¬ £¬£¬£¬£¬ÎªOncotelicºÍSAPUÌṩ°üÀ¨Ò©Îï·¢Ã÷¡¢Ò©Ñ§Ñо¿£¨ÖÊÁÏÒ©¡¢ÖƼÁ£©¡¢ÁÙ´²Ç°Ñо¿£¨Ò©Ð§¡¢Ò©´ú¡¢°²ÆÀ£©µÈÔÚÄÚµÄһվʽÁÙ´²Ç°Ñз¢Ö§³Ö£¬£¬ £¬£¬£¬£¬5ÄêÖúÁ¦OncotelicºÍSAPU¼ÓËÙÍÆ½ø20¸öÐÂÒ©ÏîÄ¿µÄINDÉ걨£¬£¬ £¬£¬£¬£¬º­¸ÇºËËáÒ©ÎïºÍÄÉÃ×ÖÆ¼ÁµÈÁ¢ÒìÒ©Î£¬ £¬£¬£¬£¬ÎªÈ«ÇòÐÂÒ©Ñз¢×¢ÈëոеĻîÁ¦ÓëÁ¢Ò춯Á¦¡£¡£¡£

OncotelicºÍSAPU¶­Ê³¤&CEOVuong Trieu ²©Ê¿ÌåÏÖ£º¡°´Ë´ÎÏàÖú½«ÎªÃÀ¸ß÷¿ª·¢ÏîÄ¿´øÀ´¸ïÃüÐÔµÄÀå¸ï¡£¡£¡£ÃÀ¸ß÷һվʽÉúÎïÒ½Ò©ÁÙ´²Ç°×ÛºÏÑз¢Ð§ÀÍÆ½Ì¨¹ØÓÚ¼ÓËÙSAPUºÍOncotelicÒ©ÎïÑз¢Àú³ÌÖÁ¹ØÖ÷Òª¡£¡£¡£ÎÒÃÇÆÚ´ýÓëÃÀ¸ß÷¼ÌÐøÉÏàÖú£¬£¬ £¬£¬£¬£¬Ð¯ÊÖÍÆ¶¯Á¢Ò쿹°©Ò©Îï¸ü¿ì½øÈëÁÙ´²½×¶Î¡£¡£¡£¡±

ÃÀ¸ß÷Ê×´´ÈË¡¢¶­Ê³¤&CEO³Â´º÷벩ʿÌåÏÖ£º¡°ºÜÊÇÐÒÔËÄܹ»ÓëOncotelicºÍSAPU¸æ¿¢Õ½ÂÔÏàÖú¡£¡£¡£ÎÒÃǽ«ÒÀÍÐÔÚÐÂÒ©Ñз¢ÁìÓòËù»ýÀÛµÄÑз¢¼¼ÊõºÍ¹ú¼ÊÂÄÀú£¬£¬ £¬£¬£¬£¬ÎªOncotelicºÍSAPUÌṩһվʽÁÙ´²Ç°Ñз¢Ð§ÀÍ£¬£¬ £¬£¬£¬£¬Ð¯ÊÖ²¢½ø£¬£¬ £¬£¬£¬£¬ÅäºÏ¼ÓËÙÐÂÒ©Ñз¢µÄÀú³Ì£¬£¬ £¬£¬£¬£¬ÎªÈ«Çò²¡»¼¿ª·¢ÐµÄÖÎÁÆÑ¡Ôñ¡£¡£¡£¡±


¹ØÓÚOncotelic

Oncotelic Therapeutics£¨Ç°ÉíΪMateon Therapeutics, Inc.£©×î³õÓÚ1988ÄêÔÚŦԼÖݽ¨É裬£¬ £¬£¬£¬£¬ÃûΪOXiGENE, Inc.£¬£¬ £¬£¬£¬£¬1992ÄêÖØÐÂÔÚÌØÀ­»ªÖÝ×¢²á£¬£¬ £¬£¬£¬£¬2016Äê¸üÃûΪMateon Therapeutics, Inc.£¬£¬ £¬£¬£¬£¬²¢ÓÚ2020Äê11Ô¸üÃûΪOncotelic Therapeutics, Inc.¡£¡£¡£¹«Ë¾ÖÂÁ¦ÓÚʹÓÃÆäÔÚÖ×ÁöÒ©Î↑·¢ÁìÓòµÄÉîֿר³¤£¬£¬ £¬£¬£¬£¬ÒÔ¸ÄÉÆ°©Ö¢»¼Õߣ¨ÓÈÆäÊÇÓÐÊý¶ù¿Æ°©Ö¢£©µÄÖÎÁÆÐ§¹ûºÍÉúÑÄÂÊ¡£¡£¡£Í¨¹ýÆìϳÖÓÐ45%¹ÉȨµÄºÏ×ÊÆóÒµGMP Biotechnology Limited£¬£¬ £¬£¬£¬£¬OncotelicÒÑ»ñµÃ¶àÏîÓÐÊý¶ù¿Æ¼²²¡È϶¨£ºÕë¶ÔÃÖÂþÐÔÄÚÉúÐÍÇÅÄÔ½ºÖÊÁö£¨DIPG£©µÄOT-101ÁÆ·¨¡¢Õë¶ÔÐþÉ«ËØÁöµÄCA4PÁÆ·¨£¬£¬ £¬£¬£¬£¬ÒÔ¼°Õë¶Ô¼±ÐÔËèϵ°×Ѫ²¡£¡£¡£¨AML£©µÄOXi 4503ÁÆ·¨¡£¡£¡£2019Äê11Ô£¬£¬ £¬£¬£¬£¬OncotelicÊÕ¹ºÁËPointR Data Inc.£¬£¬ £¬£¬£¬£¬Ö¼ÔÚ´òÔìÒ»¼ÒÓÉÈ˹¤ÖÇÄÜÇý¶¯µÄÉúÎï¿Æ¼¼¹«Ë¾¡£¡£¡£±ðµÄ£¬£¬ £¬£¬£¬£¬¹«Ë¾ÓÚ2021ÄêµÚËÄÐò¶È»ñµÃÁËAL-101£¨ÓÃÓÚ±ÇÄÚµÝËͰ¢ÆËÂð·È£©µÄ¿ª·¢È¨£¬£¬ £¬£¬£¬£¬ÍýÏ뽫ÆäÓ¦ÓÃÓÚÅÁ½ðÉ­²¡¡¢²ªÆð¹¦Ð§Õϰ­¡¢Å®ÐÔÐÔ¹¦Ð§Õϰ­¼°ÐÔÓû¼õÍËÖ¢µÄÖÎÁÆ¡£¡£¡£ÕâЩ¼²²¡¾ùÓ°Ïì×ÅÖØ´ó»¼ÕßȺÌ壬£¬ £¬£¬£¬£¬±£´æÆÈÇеÄÁÙ´²ÐèÇ󡣡£¡£ÓйØAL-101µÄÏêϸÐÅÏ¢£¬£¬ £¬£¬£¬£¬Çë²ÎÔĹ«Ë¾ÓÚ2024Äê4ÔÂ12ÈÕÏòÃÀ¹ú֤ȯÉúÒâίԱ»á£¨SEC£©Ìá½»µÄ2023Äê¶È10-K±í¸ñ±¨¸æ¡£¡£¡£

¹ØÓÚÃÀ¸ß÷

ÃÀ¸ß÷£¨¹ÉƱ´úÂ룺688202.SH£©½¨ÉèÓÚ2004Ä꣬£¬ £¬£¬£¬£¬×ܲ¿Î»ÓÚÉϺ££¬£¬ £¬£¬£¬£¬ÖÂÁ¦ÓÚΪȫÇòÖÆÒ©ÆóÒµ¡¢Ñо¿»ú¹¹¼°¿ÆÑÐÊÂÇéÕßÌṩȫ·½Î»µÄÁÙ´²Ç°ÐÂÒ©Ñо¿Ð§ÀÍ¡£¡£¡£ÃÀ¸ß÷µÄһվʽ×ÛºÏЧÀÍÒÔÇ¿ÓÐÁ¦µÄÏîÄ¿¹ÜÀíºÍ¸ü¸ßЧ¡¢¸ßÐԼ۱ȵÄÑз¢Ð§ÀÍÖúÁ¦¿Í»§¼ÓËÙÐÂÒ©Ñз¢Àú³Ì£¬£¬ £¬£¬£¬£¬Ð§Àͺ­¸ÇÒ½Ò©ÁÙ´²Ç°ÐÂÒ©Ñо¿µÄÈ«Àú³Ì£¬£¬ £¬£¬£¬£¬°üÀ¨Ò©Îï·¢Ã÷¡¢Ò©Ñ§Ñо¿¼°ÁÙ´²Ç°Ñо¿¡£¡£¡£ÖÁ2024Äêµ×£¬£¬ £¬£¬£¬£¬ÃÀ¸ß÷ÒÑΪȫÇò³¬2000¼Ò¿Í»§ÌṩҩÎïÑз¢Ð§ÀÍ£¬£¬ £¬£¬£¬£¬¼ÓÈëÑз¢Íê³ÉµÄÐÂÒ©¼°·ÂÖÆÒ©ÏîÄ¿ÒÑÓÐÔ¼520¼þIND»ñÅúÁÙ´²£¬£¬ £¬£¬£¬£¬Ó뺣ÄÚÍâÓÅÖʿͻ§ÅäºÏÉú³¤¡£¡£¡£ÃÀ¸ß÷½«¼ÌÐø×¤×ãÈ«ÇòÊÓÒ°£¬£¬ £¬£¬£¬£¬¾ÛÁ¦ÖйúÁ¢Ò죬£¬ £¬£¬£¬£¬ÎªÈËÀ࿵½¡Ð¢Ë³ÊµÁ¦£¡

¹ØÓÚÃÀ¸ß÷ºËËáÒ©ÎïÑз¢Æ½Ì¨

»ùÓÚÑϽ÷µÄ¿ÆÑ§Ì¬¶È¡¢¿ª·ÅµÄ¼¼Êõƽ̨ºÍÏȽøµÄÒÇÆ÷×°±¸£¬£¬ £¬£¬£¬£¬ÃÀ¸ß÷´òÔìÁË´ÓÐòÁÐÉè¼Æ¡¢»¯Ñ§ÐÞÊΡ¢Ä£Ê½ÐÞÊε½µÝËÍϵͳ£¬£¬ £¬£¬£¬£¬¼¯³ÉÒ©Îï·¢Ã÷¡¢Ò©Ñ§Ñо¿ºÍÁÙ´²Ç°Ñо¿µÄÒ»Ì廯×ÛºÏÐÔºËËáÒ©ÎïÑз¢Ð§ÀÍÆ½Ì¨¡£¡£¡£ÎÒÃÇ¿ÉÒÔÖª×ãÐÐÒµ¹ØÓÚÁ¢ÒìºËËáÒ©ÎïµÄÑз¢ÐèÇ󣬣¬ £¬£¬£¬£¬³Ð½ÓÒ½Ò©¹«Ë¾¼°¿ÆÑе¥Î»µÄºËËáÒ©ÎïÑз¢Ð§ÀÍ¡£¡£¡£

×ÉѯЧÀÍ

Ïà¹ØÐÂÎÅ
ÐÂÒ©Ñз¢µÚÈý´ÎÀ˳±¡ª¡ªÐ¡ºËËáÒ©Îï(Ò»)
2022-03-01
СºËËáÒ©ÎïÊÇÏÖÔÚÉú³¤×îΪѸÃ͵ĻùÒòÁÆ·¨Ö®Ò»£¬£¬ £¬£¬£¬£¬ÕýÔÚ³ÉΪÐÂÒ©Ñз¢µÚÈý´ÎÀ˳±ÖеÄٮٮÕߣ¬£¬ £¬£¬£¬£¬ÆäÖ÷Òª°üÀ¨·´Òå¹ÑºËÜÕËá (ASO)¡¢Ð¡×ÌÈÅRNA (siRNA)¡¢Ï¸Ð¡RNA (miRNA)¡¢Ð¡¼¤»îRNA (saRNA)¡¢ÐÅʹRNA (mRNA)¡¢RNAÊÊÅä (Aptamer)µÈ¡£¡£¡£
½£Ö¸ÐÄѪ¹Ü¼²²¡¡ª¡ªÐ¡ºËËáÒ©Îï(¶þ)
2022-05-16
СºËËáÒ©ÎォΪÐÄѪ¹Ü¼²²¡ÖÎÁÆÁìÓò¿ªÆôÐÂÆªÕ£¬£¬ £¬£¬£¬£¬ÏÖÔÚÃÀ¸ß÷ÔÚmRNA£¬£¬ £¬£¬£¬£¬siRNAµÈСºËËáÒ©Îï·½ÃæµÄ¶à¸öFTEÏîÄ¿ÒÔ¼°CMCЧÀÍÏîÄ¿ÒÑÆô¶¯¡£¡£¡£
¸³ÄܺËËáÒ©ÎïÁÆ·¨£¬£¬ £¬£¬£¬£¬Ó­½ÓÐÂÒ©Ñз¢µÚÈý´ÎÀ˳±
2022-06-06
ºËËáÒ©ÎïÊÆ²»¿Éµ²£¬£¬ £¬£¬£¬£¬ÎªÁ˸üºÃµØÖúÁ¦ÐÐÒµÉú³¤£¬£¬ £¬£¬£¬£¬ÃÀ¸ß÷½«ÁªºÏÒ»²¿·ÖÐÐÒµÄÚºËËáÒ©ÎïµÄÁìÅÜÆóÒµÓÚ2022Äê07Ô¿ªÕ¹Ò»³¡¹ØÓÚºËËáÒ©ÎïµÄÏßÉÏÂÛ̳£¬£¬ £¬£¬£¬£¬ÔƼ¯Ò½Ò©ÐÐÒµµÄר¼ÒѧÕߣ¬£¬ £¬£¬£¬£¬ÅäºÏÕö¿ªºËËáÒ©ÎïÑз¢¼°Ó¦ÓõÄÇ¿ÁÒÌÖÂÛ£¬£¬ £¬£¬£¬£¬´ÓÒ©ÆóºÍCROµÄÊӽǣ¬£¬ £¬£¬£¬£¬¹²»°ºËËáÒ©Îï¡£¡£¡£
¡Á
ËÑË÷ÑéÖ¤
µã»÷Çл»
¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿